MX2015012409A - Formulaciones bajas en glicerina para prevencion y tratamiento de vih. - Google Patents

Formulaciones bajas en glicerina para prevencion y tratamiento de vih.

Info

Publication number
MX2015012409A
MX2015012409A MX2015012409A MX2015012409A MX2015012409A MX 2015012409 A MX2015012409 A MX 2015012409A MX 2015012409 A MX2015012409 A MX 2015012409A MX 2015012409 A MX2015012409 A MX 2015012409A MX 2015012409 A MX2015012409 A MX 2015012409A
Authority
MX
Mexico
Prior art keywords
hiv
formulations
prevention
low
reduce
Prior art date
Application number
MX2015012409A
Other languages
English (en)
Inventor
David R Friend
Original Assignee
Conrad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conrad filed Critical Conrad
Publication of MX2015012409A publication Critical patent/MX2015012409A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

La presente invención se relaciona con formulaciones de inhibidores de nucleótidos transcriptasa inversa (NRTIs), preferiblemente ácido [2- (6- amino- purín- 9- il)- 1- metil-etoximetil]- fosfónico (tenofovir, PMPA), o un derivado funcional de éste, en donde las formulaciones contienen un bajo nivel de glicerina. Infecciones por el virus de inmunodeficiencia humana (VIH) y enfermedades relacionadas son un problema de salud pública importante a nivel mundial. Un procedimiento para el problema de VIH/SIDA es reducir el riesgo de transmisión de VIH y esto reduce el número de individuos que se convierten infectados activos.
MX2015012409A 2013-03-15 2014-03-14 Formulaciones bajas en glicerina para prevencion y tratamiento de vih. MX2015012409A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361793745P 2013-03-15 2013-03-15
PCT/US2014/028044 WO2014143883A1 (en) 2013-03-15 2014-03-14 Low-glycerin formulations for hiv treatment and prevention

Publications (1)

Publication Number Publication Date
MX2015012409A true MX2015012409A (es) 2016-06-02

Family

ID=51537553

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012409A MX2015012409A (es) 2013-03-15 2014-03-14 Formulaciones bajas en glicerina para prevencion y tratamiento de vih.

Country Status (10)

Country Link
US (1) US20160030569A1 (es)
EP (1) EP2968127A4 (es)
JP (1) JP2016519666A (es)
CN (1) CN105188664A (es)
AP (1) AP2015008726A0 (es)
BR (1) BR112015021947A2 (es)
CA (1) CA2906642A1 (es)
MX (1) MX2015012409A (es)
RU (1) RU2015144011A (es)
WO (1) WO2014143883A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112165935A (zh) * 2018-03-01 2021-01-01 诺万公司 一氧化氮释放性栓剂及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187286A (en) * 1979-01-02 1980-02-05 G&W Laboratories, Inc. Contraceptive suppository
AU783242B2 (en) * 2000-01-28 2005-10-06 Board Of Regents, The University Of Texas System Methods and devices for preventing transmission of sexually transmitted diseases
US20020136757A1 (en) * 2000-01-28 2002-09-26 Samuel Baron Methods and devices for preventing transmission of sexually transmitted diseases
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
AU2010315712B2 (en) * 2009-10-19 2014-04-17 FUJIFILM Cellular Dynamics, Inc. Cardiomyocyte production
AU2011264952B2 (en) * 2010-06-11 2014-08-14 Quarraisha Abdool Karim Topical antiviral formulations for prevention of transmission of HSV-2
CN103596556A (zh) * 2011-05-02 2014-02-19 阿普塔利斯医药科技公司 用于阴道给药的快速溶解片剂组合物
KR101811917B1 (ko) * 2012-01-19 2017-12-22 더 존스 홉킨스 유니버시티 점액 침투 강화를 나타내는 나노 입자 제형

Also Published As

Publication number Publication date
RU2015144011A (ru) 2017-04-21
JP2016519666A (ja) 2016-07-07
CA2906642A1 (en) 2014-09-18
EP2968127A4 (en) 2016-09-07
EP2968127A1 (en) 2016-01-20
CN105188664A (zh) 2015-12-23
US20160030569A1 (en) 2016-02-04
AP2015008726A0 (en) 2015-09-30
WO2014143883A1 (en) 2014-09-18
BR112015021947A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
CY1124043T1 (el) Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων
PH12018502489A1 (en) Antiviral therapy
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
MD4754B1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
PH12018501001A1 (en) Therapeutic compositions for treatment of human immunodeficiency virus
MY191100A (en) Treatment for lipodystrophy
MY186106A (en) Diagnosis, prevention and treatment of diseases of the joint
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
MX2017000059A (es) Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion.
EA201290956A1 (ru) Вакцина против вич
CY1120158T1 (el) Γλουταρυλο ισταμινη για την αγωγη και προφυλαξη παθησεων προκαλουμενων απο ιους που περιεχουν (+)rna
IN2014MN01907A (es)
EP2601967A4 (en) MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS
EP2555798A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSIONS
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
BR112014003989A2 (pt) composto, composições e métodos para inibir a replicação do hiv-1 em paciente, para tratar pacientes infectados com hiv/aids e para profilaxia de pré-exposição para tratar paciente e para prevenir a transmissão de pessoa infectada para pessoa não infectada
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
MX2015012409A (es) Formulaciones bajas en glicerina para prevencion y tratamiento de vih.
JO3641B1 (ar) تركيبة مضادات الفيروسات القهقرية
DK2948129T3 (da) Terapeutiske forbindelser
Calza Disseminated maculopapular skin rash: case report
EA201300134A1 (ru) Фармацевтическая композиция и способ лечения и профилактики заболеваний, вызванных или связанных с вич